Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C19H21NO6 |
| Molecular Weight | 359.3731 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC3=C2OCO3)C(=O)OC
InChI
InChIKey=MSOAVHHAZCMHDI-UHFFFAOYSA-N
InChI=1S/C19H21NO6/c1-5-24-19(22)15-11(3)20-10(2)14(18(21)23-4)16(15)12-7-6-8-13-17(12)26-9-25-13/h6-8,16,20H,5,9H2,1-4H3
| Molecular Formula | C19H21NO6 |
| Molecular Weight | 359.3731 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Oxodipine is a dihydropyridine calcium channel blocker that has been developed by IQB as an antihypertensive agent. Experiments on dogs have shown that oxodipine exerted a relatively specific action on blood vessels without significant intrinsic negative chronotropic properties. in addition, in Europe, the drug was involved in phase III clinical trials in and in phase II for the treatment of Hypertension. Besides, oxodipine was studied for the treatment of ischaemic heart disorders. However, these studied were discontinued.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:10:14 GMT 2025
by
admin
on
Mon Mar 31 23:10:14 GMT 2025
|
| Record UNII |
7T54300UMS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7T54300UMS
Created by
admin on Mon Mar 31 23:10:14 GMT 2025 , Edited by admin on Mon Mar 31 23:10:14 GMT 2025
|
PRIMARY | |||
|
119914-34-0
Created by
admin on Mon Mar 31 23:10:14 GMT 2025 , Edited by admin on Mon Mar 31 23:10:14 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> ENANTIOMER |
|
||
|
|
RACEMATE -> ENANTIOMER |
